Sesen Bio, Inc. (NASDAQ:SESN – Get Rating) insider Elly Ryu sold 17,289 shares of the stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $0.59, for a total transaction of $10,200.51. Following the sale, the insider now directly owns 148,624 shares of the company’s stock, valued at $87,688.16. The sale was disclosed in a document filed with the SEC, which is available through this link.
Elly Ryu also recently made the following trade(s):
- On Tuesday, February 21st, Elly Ryu sold 7,159 shares of Sesen Bio stock. The shares were sold at an average price of $0.59, for a total transaction of $4,223.81.
Sesen Bio Price Performance
Shares of SESN opened at $0.59 on Tuesday. The firm has a market cap of $119.27 million, a P/E ratio of -5.86 and a beta of 0.83. Sesen Bio, Inc. has a 1 year low of $0.37 and a 1 year high of $0.97. The company has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $0.57.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on shares of Sesen Bio in a report on Monday, December 26th. They set a “hold” rating for the company.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Sesen Bio by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 12,694,776 shares of the company’s stock valued at $7,652,000 after acquiring an additional 328,020 shares during the last quarter. BML Capital Management LLC bought a new position in shares of Sesen Bio during the 4th quarter valued at approximately $5,015,000. State Street Corp boosted its position in shares of Sesen Bio by 1.2% during the 1st quarter. State Street Corp now owns 4,339,032 shares of the company’s stock valued at $2,615,000 after acquiring an additional 52,274 shares during the last quarter. BlackRock Inc. lifted its position in Sesen Bio by 3.1% in the third quarter. BlackRock Inc. now owns 4,215,390 shares of the company’s stock worth $1,792,000 after buying an additional 126,723 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Sesen Bio in the second quarter worth $2,171,000. 16.45% of the stock is currently owned by institutional investors.
Sesen Bio Company Profile
Sesen Bio, Inc engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K.
Further Reading
- Get a free copy of the StockNews.com research report on Sesen Bio (SESN)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
